RESEARCH & DEVELOPMENT
Pharmotech's breakthrough patent is a testament to the team’s top-notch expertise and dedication to bettering global wellness. As new applications for the patent are revealed, the team will continue developing and patenting new products and applications.
Elevating the quality of life of millions of people world wide
Pharmotech is centered on identifying novel applications for cannabinol (CBD) as an antibiotic agent for bacteria such as Pseudomonas Aeruginosa and Staphylococcus Aureus. In turn, the Pharmotech's team is unearthing the power of nature to treat these deadly antibiotic-resistant bacteria. As an innovator within the phytopharma space, Pharmotech combines leading knowledge with natural, active ingredients to combat Multidrug Resistant (MDR-MRSA) bacteria.
Based in Switzerland, Pharmotech SA has access to world-renowned laboratories, universities, and research institutions. These pivotal partnerships and collaborations help accelerate the R&D process, lending way to cutting-edge biotechnology advancements.
Pseudomonas aeruginosa is a Gram negative bacteria that is commonly found in the environment e.g. soil, water and other moist locations.
With aims to become the world leader in natural medical product research, production, and distribution, Pharmotech SA is changing how the medical community treats MDR-MRSA bacteria. Reach out today for questions and product inquiries.